Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. We invite you to join us in our efforts to develop these important, next-generation treatments.
Enosi is providing an opportunity for all investors to participate in an early-stage biopharmaceutical company. Usually, this domain is occupied by Venture Capital firms. While there is an accompanying risk associated with such an opportunity, the rewards for success are also significant. Enosi’s founders and management are experienced in creating product opportunities and are dedicated to Enosi’s success.
Feldmann, Shepard and other management of Enosi are addressing serious problems in the treatment of autoimmune disease and cancer. Enosi’s unique approach comes from combining the expertise of its two founders to merge discovery technologies used in either autoimmune disease and cancer to be employed in both conditions. This is the first time this has been done.
The current therapies for autoimmune disease often render patients susceptible to serious infections, cardiovascular problems, cancer, and even new autoimmune diseases. Enosi believes that it has a solution to many of these issues in its novel EN-1001 antibody program that specifically inhibits the inflammatory switch, TNFR1. Enosi is working toward displacing 30-year-old drugs, with a $40B market, with the 21st century targeted therapeutic that it hopes will be better at defeating disease, and safer for patients. This is just what Dr. Shepard has done for breast cancer with the discovery of Herceptin.
Enosi plans to progress to Regulation A, Tier 2, financing, and then list on an exchange. The Company will entertain other strategic transactions. However, success is not guaranteed.
The Company will post developments on the Title3Funds and Enosi website as well as other public forums.
Enosi is not listed on any exchanges and therefore does not have a way to establish an independent valuation. Based on assumptions regarding the Team, products and time to a meaningful clinical endpoint, we have estimated the Net Present Value of the Company at $29,270,673.
We cannot confirm that dividends will be paid out to investors.
A summary of Enosi’s financial statement is included in the offering memorandum.